Adaptin Bio (APTN) Net Income towards Common Stockholders (2023 - 2026)

Adaptin Bio has disclosed Net Income towards Common Stockholders across 4 years of filings, most recently posting -$1.2 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 20.75% year-over-year to -$1.2 million; the TTM figure through Jun 2026 stood at -$5.4 million (down 32.76% YoY), while the FY2025 annual figure was -$4.1 million, down 66.81% from the prior year.
• Net Income towards Common Stockholders came in at -$1.2 million for Q2 2026 at Adaptin Bio, down from -$1.1 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$34155.0 in Q4 2023 to a low of -$1.7 million in Q3 2025.
• Average Net Income towards Common Stockholders over 4 years is -$895921.5, with a median of -$982193.5 recorded in 2024.
• Year-over-year, Net Income towards Common Stockholders tumbled 2479.42% in 2024 and climbed 20.75% in 2026.
• Over 4 years, Net Income towards Common Stockholders stood at -$34155.0 in 2023, then plunged by 2408.67% to -$856836.0 in 2024, then slumped by 63.44% to -$1.4 million in 2025, then advanced by 13.93% to -$1.2 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$1.2 million in Q2 2026, -$1.1 million in Q1 2026, and -$1.4 million in Q4 2025.